Compile Data Set for Download or QSAR
maximum 50k data
Found 31 Enz. Inhib. hit(s) with all data for entry = 9721
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483958((R)-4-(2-(1-cyano-3-fluoropiperidin-3-yl)benzo[d]o...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483955((R)-3-(5-(3-cyanophenyl)benzo[d]oxazol-2-yl)-3-flu...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483949((S)-3-(5-(3-cyanophenyl)-3H-imidazo[4,5-b]pyridin-...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483942((R)-3-(5-([1,1′-biphenyl]-3-yl)-1,3,4-oxadia...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483963((R)-4-(2-(1-cyano-3-fluoropiperidin-3-yl)oxazolo[5...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483964((R)-4-(2-(1-cyano-3-fluoropiperidin-3-yl)imidazo[1...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483962(3-(6-(3-cyanophenyl)oxazolo[4,5-b]pyridin-2-yl)-3-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483961(3-(6-(3-cyanophenyl)oxazolo[5,4-b]pyridin-2-yl)-3-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483960((R)-4-(2-(1-cyano-3-fluoropiperidin-3-yl)benzo[d]o...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483959((R)-2-(2-(1-cyano-3-fluoropiperidin-3-yl)benzo[d]o...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483957((R)-2-(2-(1-cyano-3-fluoropiperidin-3-yl)benzo[d]o...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483956((R)-6-(2-(1-cyano-3-fluoropiperidin-3-yl)benzo[d]o...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483953(3-(6-(3-cyanophenyl)-1H-imidazo[4,5-b]pyridin-2-yl...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483952((R)-4-(2-(1-cyano-3-fluoropiperidin-3-yl)-1H-imida...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483951((R)-4-(2-(1-cyano-3-fluoropiperidin-3-yl)-3H-imida...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483948((R)-3-fluoro-3-(5-phenyl-3H-imidazo[4,5-b]pyridin-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483944((R)-4-(5-(1-cyano-3-fluoropiperidin-3-yl)-1,3,4-ox...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483943(3-(5-([1,1′-biphenyl]-4-yl)-1,3,4-oxadiazol-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483939(2-(3-([1,1′-Biphenyl]-3-yl)-H-1,2,4-triazol-...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483945((R)-4-(5-(1-cyano-3-fluoropiperidin-3-yl)-1,3,4-ox...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483946((R)-2′-(5-(1-cyano-3-fluoropiperidin-3-yl)-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483947(3-(6-(H-pyrazol-5-yl)-1H-benzo[d]imidazol-2-yl)-3-...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483954((R)-6-(2-(1-cyano-3-fluoropiperidin-3-yl)-3H-imida...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483950(3-(5-(1H-pyrazol-5-yl)-3H-imidazo[4,5-b]pyridin-2-...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483940(3-(4-(2-Phenoxyphenyl)oxazol-2-yl)piperidine-1-car...)
Affinity DataIC50: >1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483941(3-(4-([1,1′-Biphenyl]-3-yl)oxazol-2-yl)piper...)
Affinity DataIC50: >1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483937(2-(4-Phenyl-1H-benzo[d]imidazol-2-yl)morpholine-4-...)
Affinity DataIC50: >1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483938(2-(4-(3-Cyanophenyl)-1H-benzo[d]imidazol-2-yl)morp...)
Affinity DataIC50: >1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483934(3-(6-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)piperidi...)
Affinity DataIC50: >1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483936(3-(4-(3-Cyanophenyl)-1H-benzo[d]imidazol-2-yl)pipe...)
Affinity DataIC50: >1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM483935(2-(6-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)morpholi...)
Affinity DataIC50: >1.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent